Yuval Cabilly
Co-founder & Managing Partner
Claimed by owner
Israel Biotech Fund
www.globes.co.il
May 25, 2022
חברת תרופות בינלאומית תשתף פעולה עם קרן הון סיכון ישראלית
en.globes.co.il
Apr 5, 2021
Israel Biotech Fund closes $112m second fund
en.globes.co.il
Jul 16, 2019
Israel Biotech Fund reports first closure of 2nd fund
invivo.pharmaintelligence.informa.com
May 10, 2019
Israel Looks To Nurture New Leaders For Burgeoning Biotech Sector
www.globes.co.il
Jun 29, 2016
Israel Biotech Fund begins investing $100m
About
Israel Biotech Fund (IBF) invests exclusively in Israeli and Israeli related biotech companies at all development stages. Having started its activity in late 2015, the fund has a rich portfolio with more than 16 portfolio companies at various development stages from different fields as well as significant partnerships with key market players. The fund is committed to seeking high-value returns by identifying and maximizing the success of therapeutic assets of Israel-based biotechnology companies. IBF provides its portfolio companies with hands-on guidance and the necessary resources for long-term sustainable growth. Along with its team, the fund has a group of more than 30 leading pharmaceutical and financial executives acting as advisors to the fund and its portfolio.
Founded
Investment Stages
News
(5)www.globes.co.il
May 25, 2022
חברת תרופות בינלאומית תשתף פעולה עם קרן הון סיכון ישראלית
en.globes.co.il
Apr 5, 2021
Israel Biotech Fund closes $112m second fund
en.globes.co.il
Jul 16, 2019
Israel Biotech Fund reports first closure of 2nd fund
invivo.pharmaintelligence.informa.com
May 10, 2019
Israel Looks To Nurture New Leaders For Burgeoning Biotech Sector
www.globes.co.il
Jun 29, 2016
Israel Biotech Fund begins investing $100m
The Team
(7)
YC
IZ
Ido Zairi
Co-founder & Managing Partner
DS
David Sidransky
Co-founder & Managing Partner
AK
Ariel Kamsler
Associate
MA
Mordechai Applebaum
Analyst
EA
Elaine Adler
Analyst
SS
Sarit Steinberg
Partner
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Exits
Public Offering
$55M
May 2020
$55M
Public Offering
$50M
Oct 2018
$50M
Funds
(2)
Fund 2
Apr 2021
$112M
Fund 1
Oct 2016
$66M
Israeli Portfolio
( 14 )
Company Name
Description
Founded
Business Model
Employees
Funding Stage
Raised
BioSight
Therapeutics for Oncology and Hematological Disorders
1999
B2B
1-10
C
$62.5M
Gamida Cell
Cellular and Immune Therapies
1998
B2B
51-200
Public
$310.02M
Ayala Pharmaceuticals
Targeted Therapies for People with Genetic Cancers
2017
B2B
11-50
Public
$102M
Vensica Medical
Needle-free Drug Delivery System for the Urinary Bladder
2014
B2B
1-10
Seed
$22.2M
Pharma Two B
Innovative Combinations of Previously Approved Drugs
2007
B2B
11-50
C
$46.11M
TPCera
Immunomodulatory Treatment for Autoimmune Diseases
2016
B2B
1-10
A
$3.64M
Biond Biologics
Immunotherapies for Cancer and Auto-immune Diseases
2016
B2B
11-50
C
$37M
MediWound
Scab and Scar Treatments for Severe Burns and Wounds
2000
B2B2C
51-200
Public
$181.5M
Vidac Pharma
Skin Cancer Treatment
2012
B2B
1-10
Public
$9M
Tamarix Pharma
Therapies for Apoptosis-driven Diseases
2020
B2B
1-10
Seed
undisclosed
ExoProTher Medical
Nano-particle-based Cancer Treatment
2017
B2B
1-10
Seed
$500K
Peles Therapeutics
Monoclonal Antibody Treatment for Peripheral Artery Disease
2021
B2B
1-10
Seed
undisclosed
Nectin Therapeutics
Next-generation Immunotherapy Agents
2017
B2B
11-50
A
$26M
SpliSense
RNA-based Treatment for Genetic Diseases
2016
B2B
11-50
B
$29.5M
Investments
(18)
Date
Name
Description
Round Type
Lead Investor
Follow on
Amount
Feb 2023
MediWound
Scab and Scar Treatments for Severe Burns and Wounds
Post-IPO Equity Funding
Undisclosed
Dec 2022
Nectin Therapeutics
Next-generation Immunotherapy Agents
A Round
Undisclosed
Nov 2021
Vensica Medical
Needle-free Drug Delivery System for the Urinary Bladder
Undisclosed Round
Undisclosed
Jul 2021
Peles Therapeutics
Monoclonal Antibody Treatment for Peripheral Artery Disease
Undisclosed Round
Undisclosed
Mar 2021
SpliSense
RNA-based Treatment for Genetic Diseases
B Round
Undisclosed
Jan 2021
Tamarix Pharma
Therapies for Apoptosis-driven Diseases
Seed
Undisclosed
Jan 2021
ExoProTher Medical
Nano-particle-based Cancer Treatment
Seed
Undisclosed
Dec 2020
BioSight
Therapeutics for Oncology and Hematological Disorders
C Round
Undisclosed
Mar 2020
BioSight
Therapeutics for Oncology and Hematological Disorders
C Round
Undisclosed
Feb 2020
SpliSense
RNA-based Treatment for Genetic Diseases
Seed
Undisclosed
May 2019
Ayala Pharmaceuticals
Targeted Therapies for People with Genetic Cancers
B Round
Undisclosed
Jan 2019
Biond Biologics
Immunotherapies for Cancer and Auto-immune Diseases
B Round
Undisclosed
Jul 2018
TPCera
Immunomodulatory Treatment for Autoimmune Diseases
A Round
Undisclosed
Apr 2018
Ayala Pharmaceuticals
Targeted Therapies for People with Genetic Cancers
A Round
Undisclosed
Dec 2017
Ayala Pharmaceuticals
Targeted Therapies for People with Genetic Cancers
Seed
Undisclosed
Jun 2017
Gamida Cell
Cellular and Immune Therapies
F Round
Undisclosed
Feb 2017
Pharma Two B
Innovative Combinations of Previously Approved Drugs
C Round
Undisclosed
Jun 2016
Vidac Pharma
Skin Cancer Treatment
A Round
Undisclosed
Media gallery
(0)Locations
Israel
Prof. Hillel ve-Khanan Oppenheimer St 4, Rehovot, Israel
Locations
Israel
Prof. Hillel ve-Khanan Oppenheimer St 4, Rehovot, Israel
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Watchlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,